IMARI trial

Anastomotic leakage (AL) is one of the most feared complications after rectal cancer surgery. AL leads to a significant increase in postoperative morbidity, long-term surgical complications, negative impact on quality of life, higher permanent stoma rates and impaired oncological outcomes. Despite improvement in surgical and oncological outcomes in recent years, AL still occurs in up to 20% of all patient undergoing rectal cancer surgery in the Netherlands. Of all these leaks, half will not heal by conventional treatment and might require major salvage surgery.

Many adjustable and non-adjustable risk-factors have been identified for anastomotic leakage. Modifiable surgical factors include tension on the anastomosis and anastomotic perfusion. A more recently described pathophysiological mechanism relates to the intestinal microbiome. Given the multifactorial etiology, a multi-interventional program is required for the prevention of AL.

If AL occurs, early diagnosis and “active” treatment allows for optimal control of pelvic sepsis, anastomotic healing and stoma reversal. No international consensus exists on a diagnostic pathway for early detection of AL, even though evidence is building for the use of C-reactive protein (CRP) in the early postoperative period. Active treatment with vacuum-assisted drainage (EVAC) of the abscess cavity in combination with early transanal closure of the anastomotic defect appears to improve anastomotic healing rate.

In the IMARI-trial we want to address all the interventions mentioned above within existing institutional enhanced recovery programs and prehabilitation initiatives (i.e. correction of anemia, optimization of nutritional status, cessation of smoking).